FranklinIs Connected

The Alzheimer’s Association Tennessee Chapter will present its bi-annual Research Symposium, “Advancing the Science: The Latest in Alzheimer’s and Dementia Research”

Branding Agency Franklin TN banner

The Alzheimer’s Association Tennessee Chapter will present its bi-annual Research Symposium, “Advancing the Science: The Latest in Alzheimer’s and Dementia Research”

Nashville, TN – The Alzheimer’s Association TN Chapter will present its popular biannual Research Symposium on Friday, June 17 at noon CT, 1 p.m. ET.  The symposium titled, “Advancing the Science: the latest in Alzheimer’s and dementia research,” will feature a special presentation from Dr. Rebecca Edelmayer, Ph.D., Alzheimer’s Association’s Senior Director of Scientific Engagement. The event is free and virtual; to register visit Questions or difficulty registering? Please contact Harlyn Hardin at or 615-622-4176. Social work CME and CE units are available.

In addition to the presentation by Dr. Edelmayer, the Symposium will include a supplementary panel discussion about current research updates from experts in Louisiana, Mississippi and Tennessee.

Panelists include:

§  Dr. Gwen Windham, UMMC MIND Center, Jackson, MS;

§  Dr. Elizabeth Disbrow, LSU Health, Shreveport, LA;

§  Dr. Rena Robinson, Vanderbilt University, Nashville, TN

Tremendous gains have been made in the understanding of the science and basic biology underlying Alzheimer’s disease, and these advances are leading to great strides in prevention, detection, diagnostics and therapeutic interventions. This talk will focus on the latest scientific advancements and progress in Alzheimer’s and dementia research.

The presentation will include topics such as:

  • Landscape of Alzheimer’s and Dementia Science: The presentation will cover basic facts and figures regarding Alzheimer’s and other dementias.
  • Risk and Prevalence:  Risk factors for Alzheimer’s disease will be discussed.
  • Highlights in Early Detection and Diagnosis: The presentation will include why early detection and diagnosis is important and to define biomarkers; why they are needed, and how they are used in clinical trials for Alzheimer’s.
  • Latest Advances in Clinical Trials, Treatments and Lifestyle Interventions: The seminar will include diversity in therapeutic approaches currently under investigation, as well as two to three advances in clinical trials, treatments and/or lifestyle interventions.
About Alzheimer’s Association®

The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia®. Visit or call 800.272.3900. ​​


Additional information about Dr. Edelmayer:

As senior director, Scientific Engagement for the Alzheimer’s Association®, Dr. Edelmayer leads efforts to accelerate the organization’s scientific agenda through the creation and delivery of ongoing research education. She engages with more than 75 Association chapters across the country, ensuring that communities are informed of the global progress of dementia science and the organization’s crucial role in advancing research to improve the lives of those facing Alzheimer’s and all other dementia.

Dr. Edelmayer manages initiatives designed to unite researchers and clinicians with leaders of industry, regulatory agencies and the government on topics related to biomarker testing, new investigational treatments, and use of digital health and biotech approaches for studying cognition.

She has more than 18 years of experience as a scientist and educator. She spent more than six years as a pharmacologist in the Neuroscience and Immunology Discovery Divisions at Abbott and AbbVie, where she was recognized as an emerging scientific leader. As a senior scientist, she led a digital pathology team, conducted research and supported the development of clinical therapeutics in chronic inflammatory diseases of the nervous system and the skin.

Dr. Edelmayer has lectured, published and led collaborations in areas of neurodegenerative disease, neurophysiology, inflammatory skin pathology and pain neurobiology. She completed her Ph.D. and postdoctoral training in medical pharmacology with a focus on neuropharmacology at the University of Arizona College of Medicine. She holds a bachelor’s degree in neuroscience from the University of Pittsburgh, where she also completed a National Institute of Mental Health research fellowship.

# # #